|
Cato Institute on Drugs
|
|
Evidence that opioids are not that dangerous, despite hype
One particular kind of restriction does reduce opioid misuse among Medicare beneficiaries: States have implemented Prescription Drug Monitoring Programs (PDMPs), which record a patient's opioid prescribing history. States have recently begun to require
providers to access the PDMP: we find that "must access" PDMPs significantly reduce measures of misuse in Medicare Part D.But there is no statistically significant effect [of must access PDMP's] on a key medical outcome: opioid poisoning incidents.
How is this possible?
The simplest explanation is that, despite all the hype, prescription opioids are not that dangerous, even in heavy doses, when used under medical supervision. Instead, most poisonings reflect use of diverted prescription opioids,
or black market opioids like heroin, that users obtain when doctors cut them off from prescription opioids. These alternate sources may be adulterated. Under this interpretation, restrictions on opioid prescribing might even increase opioid poisonings.
Source: Cato Institute 2016 voting recommendation on opioid crisis
, Feb 17, 2017
Legalize marijuana banking until we legalize marijuana
Marijuana is now legal under the laws of [several] states, but not under federal law. And this creates huge headaches for marijuana businesses: - Two years after Colorado fully legalized the sale of marijuana, most banks here still don't offer
services to the businesses involved.
- Financial institutions are caught between state law that has legalized marijuana and federal law that bans it.
Banks' federal regulators don't fully recognize such businesses and impose onerous reporting requirements on banks that deal with them.
- Without bank accounts, the burgeoning pot sector can't accept credit or debit cards from customers.
The best solution is repeal of federal prohibition. This is not on the policy table yet, but as more states legalize marijuana, the pressure on federal policy might just hit the boiling point.
Source: Cato Institute 2015-16 voting recommendation on Drug Reform
, Mar 31, 2016
Page last updated: Apr 30, 2021